Evidence map›Paper›PMID 33138069›Full record

ReviewLife (Basel, Switzerland)2020

Tuberculosis IRIS: Pathogenesis, Presentation, and Management across the Spectrum of Disease.

Carson M Quinn, Victoria Poplin, John Kasibante, Kyle Yuquimpo, Jane Gakuru, Fiona V Cresswell, Nathan C Bahr

Open access · goldAbstract readReview
In one paragraph

Review in Life (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 1 pooled it
8.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 1 synthesis or guideline pooled it, 64 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Tuberculous Meningitis Across the Lifespan.The Journal of infectious diseases · 2025
    Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 3 countries.

Carson M QuinnSchool of Medicine, University of California, San Francisco, CA 94143, USA.ORCID 0000-0001-8858-8563
Victoria PoplinDivision of Infectious Diseases, Department of Medicine, University of Kansas, Kansas City, KS 66045, USA.
John KasibanteInfectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda.ORCID 0000-0002-7252-4052
Kyle YuquimpoDepartment of Medicine, University of Kansas, Kansas City, KS 66045, USA.
Jane GakuruInfectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda.ORCID 0000-0003-0150-4887
Fiona V CresswellInfectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda.ORCID 0000-0002-5070-532X
Nathan C BahrDivision of Infectious Diseases, Department of Medicine, University of Kansas, Kansas City, KS 66045, USA.ORCID 0000-0002-9431-8938
University of Kansas · USInfectious Diseases Institute · UGUniversity of California, San Francisco · USUniversity of London · GB

Funding

Novel Diagnostic Development for TB Meningitis and HistoplasmosisK23NS110470 · NINDS · UNIVERSITY OF MINNESOTA · PI BAHR, NATHAN · 2019 to 2023
$1.0M
NINDS NIH HHS K23 NS110470Wellcome Trust 210772/Z/18/Z
6 · The paper itself

Abstract

Antiretroviral therapy (ART), while essential in combatting tuberculosis (TB) and HIV coinfection, is often complicated by the TB-associated immune reconstitution inflammatory syndrome (TB-IRIS). Depending on the TB disease site and treatment status at ART initiation, this immune-mediated worsening of TB pathology can take the form of paradoxical TB-IRIS, unmasking TB-IRIS, or CNS TB-IRIS. Each form of TB-IRIS has unique implications for diagnosis and treatment. Recently published studies have emphasized the importance of neutrophils and T cell subtypes in TB-IRIS pathogenesis, alongside the recognized role of CD4 T cells and macrophages. Research has also refined our prognostic understanding, revealing how the disease can impact lung function. While corticosteroids remain the only trial-supported therapy for prevention and management of TB-IRIS, increasing interest has been given to biologic therapies directly targeting the immune pathology. TB-IRIS, especially its unmasking form, remains incompletely described and more data is needed to validate biomarkers for diagnosis. Management strategies remain suboptimal, especially in the highly morbid central nervous system (CNS) form of the disease, and further trials are necessary to refine treatment. In this review we will summarize the current understanding of the immunopathogenesis, the presentation of TB-IRIS and the evidence for management recommendations.

Indexed as

acquired immunodeficiency syndromeimmune reconstitution inflammatory syndrometuberculosistuberculous meningitis

Identifiers

PMID33138069
PMCPMC7693460
OpenAlexW3097916547

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.